Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baldur Magnusson

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2019
Effective Visual Communication for the Quantitative ScientistMarc Vandemeulebroecke, Mark Baillie, Alison Margolskee, et al.
Clinical and Translational Science|April 28, 2018
How Often Do Safety Signals Occur by Chance in First-in-Human Trials?Gemma L Clayton, Asher D Schachter, Baldur Magnusson, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Rong Zhao, Shuqi Zeng, et al.
Pharmaceutical Statistics|November 1, 2018
How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientistsMarc Vandemeulebroecke, Mark Baillie, David Carr, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy VolunteersKiran Dole, Florencia Pereyra Segal, Adam Feire, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Pulmonary Pharmacology & Therapeutics|June 30, 2016
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthmaVeit J Erpenbeck, Todor A Popov, David Miller, et al.
Data in Brief|September 23, 2016
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthmaVeit J Erpenbeck, Todor A Popov, David Miller, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2016
Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum MalariaTran Tinh Hien, Nicholas J White, Nguyen Thanh Thuy-Nhien, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2019
Effective Visual Communication for the Quantitative ScientistMarc Vandemeulebroecke, Mark Baillie, Alison Margolskee, et al.
Clinical and Translational Science|April 28, 2018
How Often Do Safety Signals Occur by Chance in First-in-Human Trials?Gemma L Clayton, Asher D Schachter, Baldur Magnusson, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Rong Zhao, Shuqi Zeng, et al.
Pharmaceutical Statistics|November 1, 2018
How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientistsMarc Vandemeulebroecke, Mark Baillie, David Carr, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy VolunteersKiran Dole, Florencia Pereyra Segal, Adam Feire, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Pulmonary Pharmacology & Therapeutics|June 30, 2016
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthmaVeit J Erpenbeck, Todor A Popov, David Miller, et al.
Data in Brief|September 23, 2016
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthmaVeit J Erpenbeck, Todor A Popov, David Miller, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2016
Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum MalariaTran Tinh Hien, Nicholas J White, Nguyen Thanh Thuy-Nhien, et al.
Pageof 2